Dr. James Davison serves as Senior Translational Genomics Scientist. He joined GeneCentric Therapeutics in 2020 after serving as a Senior Study Director for Population Health at Metabolon, Inc. His prior work includes collaborating and interpreting metabolomics projects with Key Opinion Leaders (KOLs) in academia and in pharmaceutical partnerships.  His work with these clients has spanned the biological sciences spectrum and have included studies in cancer biology, immunology, metabolic syndrome, intestinal biology, and many more. Prior to Metabolon, he served as a Research Director for a basic science research lab in the Department of Anesthesiology at Duke University Medical Center. He completed his Ph.D. in 2017 at the University of North Carolina, Chapel Hill where he analyzed and interpreted RNA-seq, DNAse-seq and ChIP-Seq (transcription factor and histone) datasets to understand how the intestinal microbiota mediate chromatin and transcriptional responses of intestinal epithelia.